Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Masimo Corporation (MASI)
LOS ANGELES, Sept. 01, 2023 (GLOBE NEWSWIRE) –
Glancy Prongay & Murray LLP (“GPM”) is reminding investors of the approaching October 23, 2023 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who bought or otherwise acquired Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI) common stock between February 28 and April 26, 2023, inclusive (the “Class Period”).
The lawsuit alleges that the Company misled investors concerning its business operations and prospects, resulting in damages to investors. According to the lawsuit, investors experienced financial losses due to the alleged misrepresentations.
An Overview of Masimo Corporation
Masimo Corporation is a global medical technology company that develops and manufactures non-invasive monitoring technologies, including medical devices and sensors. The Company’s products are used in healthcare settings worldwide to improve patient outcomes and reduce the cost of care.
Investors who purchased Masimo Corporation common stock during the Class Period and suffered financial losses are encouraged to contact GPM to discuss their legal rights. The deadline to file a lead plaintiff motion is fast approaching, so affected investors should act promptly to protect their interests.
How This Lawsuit May Impact You
If you purchased Masimo Corporation common stock between February 28 and April 26, 2023, you may be eligible to participate in the class action lawsuit. By filing a lead plaintiff motion before the October 23, 2023 deadline, you can seek to recover any financial losses you suffered as a result of the alleged misrepresentations by the Company.
How This Lawsuit May Impact the World
The outcome of this class action lawsuit against Masimo Corporation could have broader implications for the medical technology industry and investor confidence in the healthcare sector. If the allegations are proven true, it may lead to increased scrutiny of corporate practices and disclosures within the industry, potentially prompting regulatory changes to protect investors and consumers.
Conclusion
It is crucial for investors who purchased Masimo Corporation common stock during the Class Period to be aware of the looming deadline to file a lead plaintiff motion in the class action lawsuit. By taking prompt action and seeking legal counsel, affected investors can protect their rights and potentially recover any financial losses suffered as a result of the alleged misrepresentations by the Company.
